Merck's Keytruda builds a commanding lead in frontline lung cancer with data from two more landmark trials
CHICAGO — Merck came to ASCO as the dominant industry player in frontline lung cancer. It’s going to leave ASCO with that rep intact — at the expense of its heavyweight rivals in the field still playing catch-up.
In two key studies out this morning, the pharma giant spelled out positive, critically important data underscoring Keytruda’s ability to fight a broad segment of the cases in the first-line lung cancer field as a monotherapy, with the Keytruda/chemo combo the best option (so far) in frontline squamous cases, where Roche tried — and largely failed — to elbow ahead this weekend.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.